News

ProteinLogic Appoints Dr Edward Gibson as Non-Executive Director

CAMBRIDGE, UK (2018-09-01) – ProteinLogic, the biomarker discovery and exploitation company, has appointed Dr Edward Gibson as Non-Executive Director. Dr Gibson holds a holds a degree in Chemistry from Bristol University, and a PhD in Biochemistry from Oxford University, where he also performed postdoctoral research. Since then, he has held a number of senior leadership roles with Bristol-Myers Squibb, focusing on commercialization and lifecycle management within the company’s oncology department, rising to becoming a member of the European oncology steering committee. He then went on to become Senior Director for New Product Strategy and EU commercialization with AVEO, as a…

ProteinLogic Presents at McGill Summer Institute on Advanced TB Diagnostics

CAMBRIDGE, UK (2018-06-25) ProteinLogic (PL), the biomarker discovery and exploitation company, was invited to present its latest findings at the 8th McGill University’s Summer Institute for Advanced TB Diagnostics, held on the 18th-22nd of June 2018, in Montreal, Canada. CEO Nicolas Huber presented PL’s exciting developments in TB diagnosis to participants from the global TB community, including members of the medical community, NGOs, epidemiologists, national TB program leaders, and industry experts. The results garnered significant interest for further implementation for collaboration and implementation of PL’s diagnostic in clinical practice, which avenues the company in now actively exploring.

ProteinLogic Joins BIVDA

CAMBRIDGE, UK (2018-06-06) – ProteinLogic the biomarker discovery and exploitation company has become an affiliate member of the British In Vitro Diagnostics Association (BIVDA). BIVDA is the national trade association for companies with major involvement and interest in the In Vitro Diagnostics (IVD) industry and has represented manufacturers and distributors of IVD products for over 25 years. Through BIVDA, ProteinLogic now has the opportunity to work with other members who share a common interest; participate and gain insight in many areas impacting the IVD industry such as regulatory updates and Brexit; be involved in championing the industry to politicians and…

ProteinLogic Presents At Bio€quity 2018, Ghent, Belgium

CAMBRIDGE, UK (2018-05-17) – ProteinLogic attended 19th Bio€quity Europe event, held in Ghent, Belgium. Bio€quity Europe pioneered the turf-neutral concept, creating an open door for all members of the financial community and business development and licensing professionals to do business with independently selected presenting companies. ProteinLogic was invited to present to a panel of investors and life-science professionals, garnering significant interest. Further panel discussions of significant interest included topics on access to the Chinese market and investment, as well as the future of EU Biotech. Further information: info@proteinlogic.com ProteinLogic ProteinLogic is a biomarker discovery and exploitation company developing novel diagnostic products…

ProteinLogic At BioTrinity 2018, London, UK

CAMBRIDGE, UK (2018-04-26) – ProteinLogic attended BioTrinity 2018, Europe’s leading biopartnering and investment conference. During the event, ProteinLogic delegates took advantage of the partnering environment to provide exposure of our technology, and our validated TB diagnostic to investors and life-sciences key players. The event included panel discussions of significant interest, especially regarding market access globally, the new life-science investment landscape, and alternative sources of funding. Further information: info@proteinlogic.com ProteinLogic ProteinLogic is a biomarker discovery and exploitation company developing novel diagnostic products that address key unmet medical needs in infection and inflammatory diseases. The first product in the pipeline is a novel…

ProteinLogic Appoints Darleen Welford as VP of Regulatory Affairs and Quality Assurance

CAMBRIDGE UK (2018- 03- 05) –  ProteinLogic, the biomarker discovery and exploitation company has appointed Darleen Welford as VP of Regulatory Affairs and Quality Assurance (RA/QA) to bring valuable global regulatory expertise, and to further the company’s RA strategy. Darleen has over 19 years’ experience in the field of In Vitro Diagnostic Medical Devices and brings with her a variety of regulatory and quality skills across the whole product life cycle, including experience of global product registrations, risk management, quality management systems and clinical study management. Before joining ProteinLogic, Darleen worked in similar roles in the IVD sector, where she…

ProteinLogic Appoints Dr Nicolas Huber as Chief Executive Officer

CAMBRIDGE, UK (2018-02-19) – ProteinLogic, the biomarker discovery company, has appointed Dr Nicolas Huber as its Chief Executive Officer. Dr Huber holds a Masters degree in electronic engineering and a PhD in Space Science from the University of Sussex. After working in the aerospace sector he transitioned to the biomedical sciences, and over the past 8 years has been focused on medical device research and commercialization. Most recently he has developed a new portfolio of devices for the treatment of cancer, and built a product development team and new business line within an established multinational. Dr Huber during this time…

48th Union World Conference on Lung Health in Guadalajara, Mexico

ProteinLogic attended the 48th Union World Conference on Lung Health held in Guadalajara, Mexico, held on 11th-14th October 2017.  The conference theme was  ‘Accelerating Toward Elimination’. There was a focus on how to accelerate toward elimination of Tuberculosis. Numerous prominent scientists and global thought leaders emphasised the need for pro-active steps to find people with Active TB and the importance of blood based rule-out triage test for Active TB. Delegates from more than 100 countries attended the four-day scientific programme of plenaries, symposia and abstracts presented by experts from around the world. The conference saw debate and discussion from public…

ProteinLogic develops a Rule-Out Test for Active TB

CAMBRIDGE, UK (2017-08-30) – ProteinLogic, a biomarker discovery company, funded by a grant by the European Union Horizon 2020 SME programme to develop a rapid point-of-care test for the diagnosis of Active Tuberculosis (TB), has achieved a significant milestone. In 2015, 10.4 million people fell ill with TB and 1.8 million died from the disease. Over 95% of TB deaths occur in low and middle-income countries. Whilst TB incidence has fallen by an average of 1.5% per year since 2000, there is an urgent need to accelerate this to a 4–5% annual decline. The World Health Organisation has set a…

ProteinLogic appoints Dr Alex Betz as Chief Scientific Officer

CAMBRIDGE, UK (2016-05-03) – ProteinLogic, the biomarker discovery and exploitation company, has appointed Dr Alex Betz as Chief Scientific Officer to manage the scientific, research, technological and developmental operations. As a long standing non-executive director of the Company, Alex has helped set the company research and scientific priorities so that they line up with the overall mission and goals of the Company Dr Betz completed a PhD on the hypermutation of immunoglobulin genes at the MRC Laboratory of Molecular Biology, Cambridge UK. After 3.5 years working as a post-doc at the Howard Hughes Medical Institute, Johns Hopkins University, Baltimore USA,…